Michael W. Dunne is a physician trained in infectious diseases. He completed his medical school training at the State University of New York Health Sciences Center in Brooklyn and Internal Medicine residency at Hartford Hospital and Yale University School of Medicine, continuing at Yale for his fellowship training in infectious diseases and pulmonary medicine. Until recently he has served as a vice president of clinical development at Pfizer, helping to guide strategic investments in the anti-infective portfolio of compounds while providing direct oversight to the clinical trial programs leading to registration. He has played a leadership role in the development of antibacterial, anti-fungal and antiviral compounds, including drugs used for the treatment of respiratory tract infection, HIV infection and malaria. He subsequently contributed to the policy group at Pfizer, serving as a Vice President of Portfolio Policy. He is a member of the infectious Diseases Society of America, the American Society of Microbiology as well as the American College of Physicians.